X4 Pharmaceuticals, Inc XFOR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2017 · data as of November 13, 2026
X4 Pharmaceuticals, Inc (XFOR) is a healthcare company listed in the US with a market value of about $319M. In the twelve months to September 30, 2026 it had revenue of $17M and net income of -$81M, a net margin of -474.7%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 5.7, 5-year revenue growth of 64% a year, a 5-year average ROIC of -52%.
About X4 Pharmaceuticals
X4 Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2017. Revenue went from $3M in 2020 to $35M in 2025, growth of about 63.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1897% over three years (dilution for shareholders). It spends 207% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17M | $35M | $3M | $0 | $0 | $0 | $3M | $0 | $0 | — | — |
| Net income | -$81M | -$79M | -$37M | -$101M | -$94M | -$89M | -$62M | -$53M | -$33M | -$22M | -$23M |
| Free cash flow | -$81M | -$86M | -$131M | -$97M | -$77M | -$72M | -$60M | -$48M | -$25M | -$22M | -$22M |
| EPS (diluted) | $0.55 | $-1.87 | $-5.59 | $-17.07 | $-45.60 | $-119.70 | $-92.70 | $-138.90 | $-2374.50 | $-1637.40 | $-41885.78 |
| Net margin | -474.7% | -225.6% | -1440.4% | — | — | — | -2071.0% | — | — | — | — |
| ROIC | — | -26.2% | -28.8% | -77.3% | -61.5% | -64.5% | -42.5% | -34.0% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $11.60, 272% above the current price; targets range from $10.00 to $13.00; the consensus rating is “Strong buy”; expected EPS is $-0.64 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is X4 Pharmaceuticals’s P/E ratio?
About 5.7, based on the last twelve months of diluted earnings per share.
Does X4 Pharmaceuticals pay a dividend?
Not currently.
Is X4 Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. X4 Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.